Oncodesign Confirms Its Very Good Results in 2021 and an Attractive Outlook For 2022

Group turnover up by 23% at €31.3 millionOperating income and revenue of €36.2M, offsetting the foreseen discontinuation of the GSK subsidy (€8M)R&D investments amounting to €7.4MNet profit/loss near the break-even point (-€0.3M)Service BU:Very strong organic growth in external turnover at +31%, reaching €27.6M,EBIT...

Related Keywords

United States ,Saclay ,France General ,France ,Canada ,Paris ,French ,American ,Arnaud Lafforgue ,Mathilde Bohin ,Les Ulis ,Philippe Genne ,University Hospital ,Investments In Research ,Research Tax Credit ,Oncodesign Group ,Business Development ,Regulatory News ,Business Units ,Artificial Intelligence ,Chief Financial Officer ,North American ,Drug Discovery ,Statutory Auditor ,Euronext Growth Market ,